Difference between revisions of "Bleomycin (Blenoxane)"
m |
m |
||
| Line 11: | Line 11: | ||
*[[Basal cell and squamous cell skin cancer]] | *[[Basal cell and squamous cell skin cancer]] | ||
*[[Bone cancer]] | *[[Bone cancer]] | ||
| + | *[[Follicular lymphoma]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
| Line 37: | Line 38: | ||
[[Category:Bone cancer medications]] | [[Category:Bone cancer medications]] | ||
[[Category:Cancer of unknown primary medications]] | [[Category:Cancer of unknown primary medications]] | ||
| + | [[Category:Follicular lymphoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
Revision as of 16:40, 11 November 2014
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant
- 1 unit of bleomycin = 1 mg of bleomycin
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Basal cell and squamous cell skin cancer
- Bone cancer
- Follicular lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Penile cancer
- Sarcoma
- Testicular cancer
- Unknown primary
Patient drug information
- Bleomycin (Blenoxane) patient drug information (Chemocare)[2]
- Bleomycin (Blenoxane) patient drug information (UpToDate)[3]
History of changes in FDA indication
- 7/31/1973: Initial FDA approval
References
- Drug index
- Chemotherapy
- DNA synthesis inhibitors
- Irritant chemotherapy
- Aggressive Non-Hodgkin lymphoma medications
- Basal cell and squamous cell skin cancer medications
- Bone cancer medications
- Cancer of unknown primary medications
- Follicular lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Penile cancer medications
- Sarcoma medications
- Testicular cancer medications
- Drugs FDA approved in 1973